Skip to content

Serotonin research published in 2011

43 studies whose primary subject is serotonin were published in 2011, up from 31 in 2010. Newest first. Back to the serotonin overview

Studies

Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD)

Pharmacology, Biochemistry, and Behavior December 15, 2011 Emmanuelle A. D. Schindler, Kuldip D. Dave, Elaine M. Smolock et al. 18 citations

RationaleAfter decades of social stigma, hallucinogens have reappeared in the clinical literature demonstrating unique benefits in medicine. The precise behavioral pharmacology of these compounds remains unclear, however.ObjectivesTwo commonly studied hallucinogens, (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD), were investigated both in vivo and...

The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue.

Neuropsychopharmacology December 14, 2011 Michael H Baumann, Mario A Ayestas, John S. Partilla et al.

The nonmedical use of 'designer' cathinone analogs, such as 4-methylmethcathinone (mephedrone) and 3,4-methylenedioxymethcathinone (methylone), is increasing worldwide, yet little information is available regarding the mechanism of action for these drugs. Here, we employed in vitro and in vivo methods to compare neurobiological effects of mephedrone and methylone with those produced by the...

Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA

Journal of Neuroinflammation December 1, 2011 Andrea Mayado, Elisa Torres, Maria D Gutierrez-Lopez et al. 8 citations

AbstractBackgroundPreconditioning is a phenomenon by which tolerance develops to injury by previous exposure to a stressor of mild severity. Previous studies have shown that single or repeated low dose MDMA can attenuate 5-HT transporter loss produced by a subsequent neurotoxic dose of the drug. We have explored the mechanism of delayed preconditioning by low dose MDMA.MethodsMale Dark Agouti...

Genetic Deletion of Trace Amine 1 Receptors Reveals Their Role in Auto-Inhibiting the Actions of Ecstasy (MDMA)

Journal of Neuroscience November 23, 2011 Benjamin Di Cara, Roberto Maggio, Gabriella Aloisi et al. 97 citations

“Ecstasy” [3,4-methylenedioxymetamphetamine (MDMA)] is of considerable interest in light of its prosocial properties and risks associated with widespread recreational use. Recently, it was found to bind trace amine-1 receptors (TA 1 Rs), which modulate dopaminergic transmission. Accordingly, using mice genetically deprived of TA 1 R ( TA 1 -KO ), we explored their significance to the actions of...

Adolescent pre‐exposure to ethanol and 3,4‐methylenedioxymethylamphetamine (MDMA) increases conditioned rewarding effects of MDMA and drug‐induced reinstatement

Addiction Biology October 13, 2011 Bruno Ribeiro Do Couto, Manuel Daza‐losada, Marta Rodrı́guez-arias et al. 26 citations

ABSTRACT Many adolescents often take ethanol (EtOH) in combination with 3,4‐methylenedioxymethylamphetamine (MDMA). In the present work, we used a mouse model to study the effect of repeated pre‐exposure during adolescence to EtOH (2 g/kg), MDMA (10 or 20 mg/kg) or EtOH + MDMA on the rewarding and reinstating effects of MDMA in the conditioned place preference (CPP) paradigm. Pre‐exposure to...

Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neurotoxicity: implications for mechanisms of neurotoxicity.

Synapse October 2011 Melanie Mueller, Jie Yuan, Concepcion Maldonado Adrian et al.

3,4-Methylenedioxymethamphetamine (MDMA)'s O-demethylenated metabolite, 3,4-dihydroxymethamphetamine (HHMA), has been hypothesized to serve as a precursor for the formation of toxic catechol-thioether metabolites (e.g., 5-N-acetylcystein-S-yl-HHMA) that mediate MDMA neurotoxicity. To further test this hypothesis, HHMA formation was blocked with dextromethorphan (DXM), which competitively...

Self‐administered MDMA produces dose‐ and time‐dependent serotonin deficits in the rat brain

Addiction Biology September 28, 2011 Jennifer Do, Susan Schenk 37 citations

ABSTRACT 3,4‐Methylenedioxymethamphetamine (MDMA) use and abuse have been increasing worldwide. Of concern, exposure to high doses of MDMA decreases several markers of serotonin (5HT) neurotransmission and produces deficits in tissue levels of 5HT. Studies in laboratory animals have been conducted primarily following large doses (20.0–80.0 mg/kg) of experimenter‐administered MDMA, but it is...

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Neuropsychopharmacology September 28, 2011 Boris B. Quednow, Michael Kometer, Mark A. Geyer et al. 241 citations

The serotonin-2A receptor (5-HT(2A)R) has been implicated in the pathogenesis of schizophrenia and related inhibitory gating and behavioral inhibition deficits of schizophrenia patients. The hallucinogen psilocybin disrupts automatic forms of sensorimotor gating and response inhibition in humans, but it is unclear so far whether the 5-HT(2A)R or 5-HT(1A)R agonist properties of its bioactive...

New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.

Bioorganic & Medicinal Chemistry August 18, 2011 Sandeep Chaudhary, Shashikanth Ponnala, Onica Legendre et al.

A series of C1, C2, C3 and N6 analogs of nantenine (2) was synthesized and evaluated in 5-HT(2A) and α(1A) receptor functional assays. Alkyl substitution of the C1 and N6 methyl groups of nantenine provided selective 5-HT(2A) and α(1A) antagonists, respectively. The C2 alkyloxy analogs studied were generally selective for α(1A) versus 5-HT(2A). The C3 bromo analog 15 is one of the most potent...

DOI: 10.1016/j.bmc.2011.08.019 (opens in new tab) Full text (opens in new tab) Aporphines Receptors, adrenergic, alpha-1 Receptor, serotonin, 5-ht2a Structure-activity relationship

Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine (“Ecstasy”)/polydrug users

Psychopharmacology August 1, 2011 Adrian P. Burgess, Louise Venables, Helena Jones et al. 26 citations

Objectives Ecstasy is a recreational drug whose active ingredient, 3,4-methylenedioxymethamphetamine (MDMA), acts predominantly on the serotonergic system. Although MDMA is known to be neurotoxic in animals, the long-term effects of recreational Ecstasy use in humans remain controversial but one commonly reported consequence is mild cognitive impairment particularly affecting verbal episodic...

Sex Differences in the Effects of MDMA (Ecstasy) on Plasma Copeptin in Healthy Subjects

The Journal of Clinical Endocrinology & Metabolism June 30, 2011 Linda D. Simmler, Cédric M. Hysek, Matthias E. Liechti 91 citations

Abstract Background: 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) misuse is associated with hyponatremia particularly in women. Hyponatremia is possibly due to inappropriate secretion of plasma arginine vasopressin (AVP). Objective: To assess whether MDMA increases plasma AVP and copeptin in healthy male and female subjects and whether effects depend on MDMA-induced release of serotonin...

Sensitization to MDMA locomotor effects and changes in the functionality of 5-HT2A and D2 receptors in mice

Behavioural Pharmacology June 29, 2011 María José Varela, José Brea, Marı́a Isabel Loza et al. 18 citations

The behavioral and neurochemical adaptations related to chronic 3,4-methylenedioxymethamphetamine (MDMA) treatment are largely unknown. In this study, we assessed whether repeated administration of MDMA would induce (a) context-dependent locomotor sensitization in mice and (b) changes in serotonin 5-HT(2A) and dopamine D₂ receptor functionality as measured by [³⁵S]GTPγS binding. Mice were...

5-HT2A receptor signalling through phospholipase D1 associated with its C-terminal tail.

Biochemical Journal June 15, 2011 Zoë Barclay, Louise Dickson, Derek N Robertson et al.

The 5-HT2AR (5-hydroxytryptamine-2A receptor) is a GPCR (G-protein-coupled receptor) that is implicated in the actions of hallucinogens and represents a major target of atypical antipsychotic agents. In addition to its classical signalling though PLC (phospholipase C), the receptor can activate several other pathways, including ARF (ADP-ribosylation factor)-dependent activation of PLD...

In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users

Archives of General Psychiatry June 6, 2011 David Erritzøe, Vibe G. Frøkjær, Klaus K. Holst et al. 86 citations

We found evidence that MDMA but not hallucinogen use is associated with changes in the cerebral presynaptic serotonergic transmitter system. Because hallucinogenic drugs primarily have serotonin(2A) receptor agonistic actions, we conclude that the negative association between MDMA use and cerebral SERT binding is mediated through a direct presynaptic MDMA effect rather than by the serotonin(2A)...

Identifying the serotonin transporter signal in Western blot studies of the neurotoxic potential of MDMA and related drugs

Synapse June 3, 2011 Michael W. McLane, Una D. Mccann, George A. Ricaurte 11 citations

A number of published studies have questioned the serotonin neurotoxic potential of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and related drugs (fenfluramine, p-chloroamphetamine) based upon results from Western blot studies using a custom synthesized serotonin transporter (SERT) antibody that found no reduction in the abundance of a 50kDa protein after substituted amphetamine...

RESIDUAL NEUROCOGNITIVE FEATURES OF ECSTASY USE: A RE‐INTERPRETATION OF HALPERN ET AL. (2011) CONSISTENT WITH SEROTONERGIC NEUROTOXICITY

Addiction June 3, 2011 A. C. Parrott 12 citations

Halpern et al. 1 presented some interesting findings from a study of abstinent ecstasy users in Salt Lake City, USA. Their ecstasy group reported comparatively slight use of all psychoactive drugs, both legal and illicit, and were therefore different from the typical user who often takes a range of other drugs. Their control group comprised similar-aged occasional rave attendees, who had never...

Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice.

Psychopharmacology June 2011 John P Dougherty, Vincent J. Aloyo

The serotonin (5-HT) 2A receptor is implicated in numerous psychiatric disorders, making it an important, clinically relevant target. Despite the availability of transgenic mouse lines, the native mouse 5-HT(2A) receptor is not well-characterized. The goals of the current study were to determine 5-HT(2A) and 5-HT(2C) receptor densities in mouse cortex, establish a pharmacological profile of the...

Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats

British Journal of Pharmacology May 26, 2011 Ján Kehr, Fumio Ichinose, Shimako Yoshitake et al.

BACKGROUND AND PURPOSE: The designer drug 1-(4-methylphenyl)-2-methylaminopropan-1-one (4-methylmethcathinone, mephedrone) is reported to possess psychostimulant, entactogenic and hallucinogenic effects. The purpose of this study was to examine the effects of acute administration of mephedrone on extracellular levels of dopamine (DA) and 5-HT in the nucleus accumbens of awake rats and compare...